Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Non-Current Liabilities (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $91.9 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 26.0% to $91.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.9 million through Dec 2025, down 26.0% year-over-year, with the annual reading at $91.9 million for FY2025, 26.0% down from the prior year.
  • Total Non-Current Liabilities hit $91.9 million in Q4 2025 for Seres Therapeutics, down from $97.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $407.1 million in Q2 2024 to a low of $91.9 million in Q4 2025.
  • Historically, Total Non-Current Liabilities has averaged $239.8 million across 5 years, with a median of $223.7 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 59.54% in 2022 and later crashed 73.25% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $211.9 million in 2021, then soared by 59.54% to $338.0 million in 2022, then grew by 18.88% to $401.8 million in 2023, then tumbled by 69.09% to $124.2 million in 2024, then decreased by 26.0% to $91.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for MCRB at $91.9 million in Q4 2025, $97.8 million in Q3 2025, and $108.9 million in Q2 2025.